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Summary
Background: A number of experimental and clinical studies have demonstrated a
cardioprotective effect of statins; however, the effect of atorvastatin on cardiac
function in patients with an acute myocardial infarction (AMI) has not been estab-
lished.
Methods and results: Thirty consecutive patients with an AMI (16 males and 14
females) were enrolled. All the patients underwent successful percutaneous coro-
nary intervention in the early phase after the onset of an AMI. Patients with a total
cholesterol level >200mg/dL on admission (n = 14) were assigned to the atorvastatin
group. They began taking 10mg of atorvastatin daily within 48 h after the onset of
the AMI, while the other patients (n = 16) did not receive atorvastatin and served
as the control group. Echocardiography and blood sampling to measure brain natri-
uretic peptide (BNP) and atrial natriuretic peptide (ANP) levels were repeated on the
2nd day (2D), 3 weeks (3W), 12 weeks (12W), and 24 weeks (24W) after the onset of
the AMI. The percentage of patients with a high BNP level (BNP > 20 pg/mL) was sig-
niﬁcantly decreased from 2D to 24W in the atorvastatin group, but not in the control
group (100 to 57% in the atorvastatin group, p < 0.05; 100 to 80% in the control group,
n.s.). Similar results also occurred with respect to the ANP level (ANP > 40 pg/mL)
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(62 to 21% in the atorvastatin group, p < 0.05; 57 to 40% in the control group, n.s.). The
left ventricular ejection fraction was signiﬁcantly higher in the atorvastatin group than
the control group at 3W (66.0± 7.8% vs. 56.5± 11.8%, p < 0.05) and 24W (67.5± 9.2%
vs. 59.7± 9.8%, p < 0.05). In the atorvastatin group, the left ventricular systolic diam-
eter was signiﬁcantly decreased at 24W compared with that at 2D (37.1± 8.0mm to
31.4± 6.5mm, p < 0.05).
Conclusions: Initiation of atorvastatin in the early phase of an AMI has beneﬁcial
effects on cardiac function, probably by improving left ventricular remodeling.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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were evaluated with Student’s t-test in the case
of continuous variables and a 2 test in the case
of categorical variables. Repeated measurement© 2008 Japanese Colleg
reserved.
ntroduction
he 3-hydroxy-3-methylglutaryl coenzyme A reduc-
ase inhibitors (statins), which are the most
ffective cholesterol-lowering agents, are attract-
ng much attention because of their pleiotropic
ffects. A number of clinical trials have been
esigned to investigate the effects of statins against
eart failure by various types of heart diseases.
osuvastatin reduced the risk of cardiovascular hos-
italization in older patients with systolic heart
ailure [1]. Statin therapy reduced mortality in
atients with heart failure [2—5], and improved car-
iac function in patients with symptomatic dilated
ardiomyopathy [6]. These beneﬁcial effects of
tatins in heart failure are predominantly assumed
o be independent of lipid-lowering.
Acute myocardial infarction (AMI) is one of the
ost serious health issues in developed countries.
rimary percutaneous coronary intervention (PCI) is
n effective therapy in the acute phase of an AMI,
nd >70% of patients undergo primary PCI in Japan.
n spite of these efforts, heart failure is still a criti-
al complication which determines the prognosis of
MI patients. In the present study, we investigated
he effects of early administration of atorvastatin
n cardiac function in patients with AMI who under-
ent primary PCI.
ethods
tudy design and patient population
prospective, non-randomized, single-center clin-
cal trial was conducted involving 30 eligible
onsecutive patients with AMI who were admitted
etween May 2004 and March 2006. The proto-
ol was in agreement with the guidelines of the
thics committee in our institution, and written
nformed consent was obtained from each patient
efore they were enrolled in the study. An AMI
as diagnosed by prolonged chest pain (>30min),
A
o
g
wT elevation in electrocardiography, positive tropo-
ine T, and increased serum creatine phosphokinase
>2 times). The patients with severe renal fail-
re, hepatic disease, a previous AMI, and those
aking lipid-lowering treatment on admission were
xcluded.
All the patients underwent successful PCI within
2 h after the onset of the AMI. Patients with a total
holesterol level >200mg/dL (n = 14) were assigned
o the atorvastatin group. They began taking 10mg
torvastatin daily within 48 h after the AMI onset.
he other patients (n = 16) were treated without
torvastatin and served as the control group. Con-
omitant drugs, except for ticlopidine, that was
iscontinued 4—8 weeks after reperfusion therapy,
ere continued during the study period. Echocar-
iography and blood sampling to measure brain
atriuretic peptide (BNP) and atrial natriuretic pep-
ide (ANP) levels were repeated on the 2nd day
2D), 3 weeks (3W), 12 weeks (12W), and 24 weeks
24W) after the onset of the AMI.
oronary intervention
CI was performed in a standard manner with or
ithout stent placement, and succeeded to reper-
use more than TIMI III. After PCI, all patients
eceived aspirin (100mg) and ticlopidine (100mg)
wice daily for at least 4 weeks.
tatistical analysis
tatistical analysis was performed with Stat View
.0.1 statistical software (SAS Institute Inc., Cary,
C, USA). Quantitative data are presented as the
ean± S.D. Differences between the two groupsNOVA was used to compare the sequential changes
f variables during the follow-up between the two
roups. Correlations between variables of interest
ere analyzed using Pearson’s correlation coefﬁ-
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cient. A p-value<0.05 was considered statistically
signiﬁcant.
Results
Patient characteristics and clinical data
The present study consisted of 30 patients. Four-
teen patients comprised the atorvastatin group and
16 patients were in the control group. The clinical
characteristics of the patients are shown in Table 1.
The percentage of males and former smoking his-
tory were signiﬁcantly higher in the control group
compared with the atorvastatin group (p < 0.05
for each). Other baseline data, including blood
pressure, creatinine, glycosylated hemoglobin, and
uremic acid levels were not signiﬁcantly different
between the two groups. The culprit artery for the
AMI, duration of time from AMI onset-to-admission,
the maximum CPK level, and the rate of restenosis
s
p
T
l
Table 1 Clinical characteristics
C
Age 70
Male/female 13
Body mass index 22
Systolic blood pressure (mmHg) 11
Diastolic blood pressure (mmHg) 70
Creatinine (mg/dL) 0.
HbA1c (%) 6.
Uremic acid (mg/dL) 5.
Coronary risk factor (%)
Diabetes mellitus 25
Hypertension 43
Former smoking history 81
Family history 0
Culprit artery (%)
RCA 43
LAD 44
LCx 13
Concomitant drugs (%)
ACE inhibitors or ARBs 62
Ca2+ channel blockers 37
Nicorandil 18
 receptor blockers 6.
Diuretics 12
Time from onset to admission (hours) 4.
Maximum CPK (IU/L) 21
Rate of restenosis (%) 18
Values aremean± S.D. *P < 0.05 vs. control HbA1c, glycosylated hemo
ing artery; LCx, left circumﬂex artery; ACE, angiotensin-convertin
phosphokinase.Y. Teshima et al.
nvestigated at 12W were not signiﬁcantly differ-
nt between each group. Concomitant drugs made
o signiﬁcant differences between the two groups
Table 1).
ffects on cholesterol and triglyceride
evels
he changes in total cholesterol, triglyceride, low-
ensity lipoprotein (LDL)-cholesterol, and high-
ensity lipoprotein (HDL)-cholesterol levels are
hown in Table 2. Total cholesterol and triglyc-
ride levels were signiﬁcantly higher in the
torvastatin group at 2D. Atorvastatin treatment
igniﬁcantly decreased both the total choles-
erol and LDL-cholesterol levels at 24W (p < 0.01).
otal cholesterol and LDL-cholesterol levels were
igniﬁcantly lower in the atorvastatin group com-
ared with the control group at 24W (p < 0.05).
here were no signiﬁcant differences in HDL
evels.
ontrol (n = 16) Atorvastatin (n = 14)
± 11.1 63± 12.1
/3 6/8*
.4± 4.0 24.5± 3.2
9.2± 19.7 122.8± 22.5
.9± 14.6 69.1± 14.7
91± 0.18 0.91± 0.39
3± 1.59 6.5± 1.26
3± 1.2 6.3± 1.5
.0 35.7
.8 14.3
.3 28.6*
7.1
36
43
21
.5 50.0
.5 21.4
.8 50.0
3 7.1
.5 7.1
75± 4.25 4.29± 1.82
00± 1287 2742± 3032
.8 28.6
globin; RCA, right coronary artery; LAD, left anterior descend-
g enzyme; ARB, angiotensin receptor blocker; CPK, creatine
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Table 2 Changes in total cholesterol, triglyceride, LDL-cholesterol, and HDL-cholesterol levels by atorvastatin
treatment
Control Atorvastatin
2D 24W 2D 24W
T-chol (mg/dL) 170.6 ± 37.1 188.6 ± 26.1 216.0 ± 25.4* 162.1 ± 14.9*,#
TG (mg/dL) 84.2 ± 35.8 113.1 ± 47.1 156.1 ± 110.7* 120.7 ± 67.2
LDL-C (mg/dL) 105.5 ± 35.6 108.0 ± 28.8 127.8 ± 27.1 82.3 ± 19.4*,#
HDL-C (mg/dL) 50.6 ± 9.7 52.8 ± 9.0 48.4 ± 10.1 54.6 ± 10.5
g point. #P < 0.01 vs. 2D in the same group. T-chol, total cholesterol;
HDL-C, high-density lipoprotein cholesterol.
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Figure 1 Effect of atorvastatin on plasma BNP level.
(A) Comparison of mean± S.D. values between the con-
trol and atorvastatin groups at each sampling point. (B)
The percentage of patients with an elevated BNP levelValues are mean± S.D. *P < 0.05 vs. control at the same samplin
TG, triglycerides; LDL-C, low-density lipoprotein cholesterol;
ffects of statin treatment on plasma BNP
nd ANP levels
ig. 1A shows the mean± S.D. values of BNP
evel in the control and atorvastatin groups at
he each sampling point. There were no sig-
iﬁcant differences between the two groups
To reduce the possible inﬂuence of variance of
alues, we classiﬁed the subjects into two groups
y cut-off line (20 pg/mL). In the control group,
he percentage of patients with a high BNP level
as higher throughout the follow-up period and still
0% at 24W (Fig. 1B). The percentage of patients
ith a high BNP level decreased gradually and was
igniﬁcantly lower at 24W compared with that at
D in the atorvastatin group (100 to 57%, p < 0.05)
Fig. 1C). Similar results were also observed with
espect to ANP levels. There were no signiﬁcant
ifferences between the two groups in ANP val-
es at the each sampling point (Fig. 2A). The
ercentage of the patients with a high ANP level
>40 pg/mL) was signiﬁcantly decreased at 12W
nd 24W compared to that at 2D in the atorvas-
atin group (62% at 2D vs. 23% at 12W and 21%
t 24W, p < 0.05 for each) (Fig. 2C), although no
igniﬁcant difference existed in the control group
Fig. 2B).
ffects of statin therapy on left ventricular
jection fraction
n Fig. 3, each line represents the change of left
entricular ejection fraction (LVEF) in each patient.
torvastatin signiﬁcantly improved the LVEF from
8.2± 10.5% to 67.5± 9.2% at 24W (p < 0.05), while
o difference was noted in the control group
Fig. 3A). Fig. 3B shows the comparison of LVEF
etween the two groups at each sampling point dur-
ng follow-up. The LVEF in the atorvastatin group
as signiﬁcantly higher than in the control group at
W (66.0± 7.8% vs. 56.5± 11.8%; p < 0.05) and 24W
67.5± 9.2% vs. 59.7± 9.8%; p < 0.05).
(>20 pg/mL) at the various time points in the control
group. (C) The percentage of patients with an elevated
BNP level in the atorvastatin group. Atorvastatin treat-
ment reduced the percentage of an elevated BNP level
at 24W compared to 2D. *P < 0.05 vs. 2D.
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Figure 2 Effect of atorvastatin on plasma ANP level. (A)
Comparison of mean± S.D.; values between the control
and atorvastatin groups at each sampling point. (B) The
percentage of patients with a high ANP level (>40 pg/mL)
at the various time points in the control group. (C) The
Figure 3 Effect of atorvastatin on left ventricular ejec-
tion fraction (LVEF). (A) Changes in LVEF in each group.
Each line represents the changes in LVEF in each patient.
Atorvastatin signiﬁcantly improved the LVEF, while no
signiﬁcant changes were observed in the control group.
*P < 0.05 vs. 2D. (B) Comparison of LVEF between the con-
trol and atorvastatin groups at each sampling point. Gray
bar represents the control group and black bar repre-
s
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changes and LVEF and LVDs changes follow-
ing atorvastatin treatment. The changes in the
total cholesterol level had no correlation with
Figure 4 Changes in LVDd and LVDs in the control andpercentage of patients with a high ANP level in the
atorvastatin group. Atorvastatin treatment reduced the
percentage of high ANP levels at 12W and 24W compared
to 2D. *P < 0.05 vs. 2D.
Changes of left ventricular diameter
Fig. 4 shows changes in the left ventricular dias-
tolic diameter (LVDd) and systolic diameter (LVDs)
in each patient from 2D to 24W. The LVDd in the con-
trol group tended to increase, but not signiﬁcantly.
The LVDs in the atorvastatin group decreased signif-
icantly (p < 0.05), while no signiﬁcant change was
demonstrated in the control group.Correlation between cholesterol changes
and LVEF and LVDs changes
To investigate if the improved cardiac function
was dependent or independent of lipid-lowering,
a
L
d
t
Lents the atorvastatin group. LVEF was signiﬁcantly higher
n the atorvastatin group at 3W and 24W. *P < 0.05 vs.
ontrol.
e examined the correlation between cholesteroltorvastatin groups. Each line represents the changes in
VDd or LVDs in each patient. The LVDs was signiﬁcantly
ecreased in the atorvastatin group, but not in the con-
rol group. No signiﬁcant difference was shown in the
VDd. *P < 0.05 vs. 2D.
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warly atorvastatin therapy improves cardiac functio
he LVEF (r = 0.098, p = 0.282) and LVDs changes
r = 0.172, p = 0.144). There were also no correla-
ions between LDL-cholesterol changes and LVEF
r = 0.001, p = 0.952) and LVDs changes (r = 0.135,
= 0.345).
iscussion
n the present study, we showed that initiating ator-
astatin therapy early after the onset of an AMI
ecreased plasma ANP and BNP levels and improved
VEF by reducing LVDs.
Because of the variance of values among each
atient, we classiﬁed the subjects into two groups
y cut-off line (20 pg/mL for BNP and 40 pg/mL
or ANP). In the atorvastatin group, the percentage
f patients with an elevated ANP level tended to
ecrease at 3W and was signiﬁcantly decreased at
2W and 24W. These short-term effects of atorvas-
atin agree with the results of the LVEF that was
mproved at 3W. The effects on BNP were slower
han ANP, and the percentage of patients with an
levated BNP level tended to decrease at 12W and
igniﬁcantly decreased at 24W with atorvastatin
reatment. We have no reasonable explanation for
he delayed BNP response because generally, BNP
s considered a more sensitive indicator of myocar-
ial injury. The study population, a large part of
hom had relatively mild cases of AMI, may have
nﬂuenced the present results.
We showed improvement in the LVEF during the
ollow-up period in the atorvastatin group, and
ecreased LVDs predominantly contributed to an
ncrease in the LVEF. These results are consis-
ent with previous reports that statin therapy for
months decreased left ventricular end-systolic
olume in patients with idiopathic dilated car-
iomyopathy [6] and that pitavastatin treatment
or 6 months reduced LVDs in ischemic and non-
schemic heart failure [7]. On the other hand,
ola et al. [8] reported that both LVDd and LVDs
ere decreased by atorvastatin treatment for 12
onths. Taking these results into account, statin
reatment may initially decrease LVDs and subse-
uently decrease LVDd after 6 months to improve
he LVEF. Furthermore, we found that the effect of
torvastatin treatment on LVEF appeared within 3
eeks and the LVDs tended to decrease. This is the
rst report that shows a short duration of statin
reatment (3 weeks) improved left ventricular sys-
olic function.
The mechanisms of cardioprotective effects by
tatins have not been fully established. In the
resent study, changes in total cholesterol and LDL-
holesterol levels had no correlation with changes
t
t
n
i
opatients with acute myocardial infarction 63
n LVEF and LVDs. This result indicates that the
ardioprotective effect of atorvastatin is inde-
endent of lipid-lowering and may be mediated
y commonly called pleiotropic effects. Kodama
t al. [9] reported that atorvastatin suppressed
ro-inﬂammatory effects of vascular endothelial
rowth factor (VEGF) and placental growth fac-
or (P1GF) by increasing soluble Fms-like tyrosine
inase 1 (sFlt-1), and improved LVEF at 6 months
fter AMI. In the present study, LVEF was signif-
cantly improved 3 weeks after the AMI onset.
t is hard to explain the discrepancy of timing
hen atorvastatin treatment showed improvement
n LVEF. Other mechanisms of anti-inﬂammatory
ffects or increased coronary ﬂow or reduced
eripheral resistance by improvement of endothe-
ial function [10] may be associated with the early
ffects of atorvastatin observed in the present
tudy.
Angiotensin-converting enzyme inhibitors
11,12], -adrenoreceptor blockers [13], and
itrates [14] have been shown to have beneﬁcial
ffects on cardiac function after an AMI. Fur-
hermore, clinical evidence has revealed that
ldosterone blockers reduce morbidity and mortal-
ty in patients with an AMI [15,16]. In spite of these
arious tools, we frequently encounter difﬁculties
sing these drugs concomitantly in the early period
f an AMI because of lower blood pressure. Statins
ave a great advantage over other cardioprotective
gents by having little impact on blood pressure.
Although PCI is the most effective therapy in the
cute phase of an AMI, heart failure is still a criti-
al complication which determines the prognosis of
MI patients. In agreement with the present results,
ecent reports showed that early statin treatment
or AMI patients decreased the risk of congestive
eart failure [17] and reduced long-term mortality
18]. These results indicate that the combination
f PCI and statin treatment may be a potent and
romising therapeutic strategy to improve progno-
is after an AMI.
tudy limitations
mong baseline characteristics, the percentage
f males, serum triglyceride levels, and for-
er smoking history were signiﬁcantly different
etween the control and atorvastatin groups.
igher serum triglyceride levels in the statin group
ere expected considering patients were assigned
o the control or atorvastatin groups based on the
otal cholesterol level. In the AMI patients with a
ormal cholesterol level, gender (male) and smok-
ng history may emerge as an important indicator
f risk for cardiovascular events. Considering the
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[
[
[
[
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[
[
[64
inﬂuence of gender differences and smoking on
endothelial function [19] and atherosclerosis [20],
we cannot exclude the possible effects of these
differences on the present results.
In the present study, we used the total choles-
terol level to assign patients to the control or
atorvastatin groups because guidelines from the
Japan Atherosclerosis Society published in 2002
designated the total cholesterol level as one of the
major criteria for dyslipidemia [21]. The criteria
were revised in 2007, and the LDL-cholesterol level
was considered a major criterion for dyslipidemia
[22]. The guideline also recommended starting
medication in patients with ischemic heart disease
if the total cholesterol level was >200mg/dL [21].
Therefore, we thought that 200mg/dL was a rea-
sonable threshold at which to start statin treatment
in the present study.
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